28 Patients in pooled analysis of (3) trials in m
Post# of 151961
(Total Views: 468)
Posted On: 04/03/2025 11:03:16 AM
28 Patients in pooled analysis of (3) trials in mTNBC presented in 2022 to ASCO.
PFS 3.8 mos.
OS 6.6 mos.
(Subset)
PFS 6.1 mos
OS.... Exceeding 12 mos.
have an expected survival of 3 mos...that's pretty dire...(thought it was 6 mos.)
Difficult for me to understand how EXCEEDING 12 mos...and pushing (3) plus years on OS is not going to be lauded as Blowing the doors off SOC.
What's this Poster going to look like...with some of these ladies still walking around?
PFS 3.8 mos.
OS 6.6 mos.
(Subset)
PFS 6.1 mos
OS.... Exceeding 12 mos.
have an expected survival of 3 mos...that's pretty dire...(thought it was 6 mos.)
Difficult for me to understand how EXCEEDING 12 mos...and pushing (3) plus years on OS is not going to be lauded as Blowing the doors off SOC.
What's this Poster going to look like...with some of these ladies still walking around?
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼